|
Eton Pharmaceuticals, Inc. (Eton) DCF Avaliação
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Eton Pharmaceuticals, Inc. (ETON) Bundle
Ganhe insights sobre sua análise de avaliação Eton Pharmaceuticals, Inc. (Eton) usando nossa calculadora DCF de última geração! Este modelo do Excel é pré -carregado com dados reais de eton, permitindo ajustar as previsões e suposições para um cálculo preciso do valor intrínseco da Eton Pharmaceuticals.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0 | .0 | 21.8 | 21.3 | 31.6 | 35.6 | 40.1 | 45.1 | 50.8 | 57.2 |
| Revenue Growth, % | 0 | -95.93 | 55879.49 | -2.66 | 48.9 | 12.58 | 12.58 | 12.58 | 12.58 | 12.58 |
| EBITDA | -18.2 | -26.5 | -1.1 | -6.5 | -.3 | -16.9 | -19.0 | -21.4 | -24.0 | -27.1 |
| EBITDA, % | -1893.01 | -67846.15 | -5.13 | -30.52 | -0.91966 | -47.32 | -47.32 | -47.32 | -47.32 | -47.32 |
| Depreciation | .4 | .7 | .4 | 1.8 | .9 | 11.4 | 12.8 | 14.4 | 16.2 | 18.3 |
| Depreciation, % | 46.61 | 1669.23 | 2.05 | 8.31 | 2.85 | 31.96 | 31.96 | 31.96 | 31.96 | 31.96 |
| EBIT | -18.6 | -27.1 | -1.6 | -8.3 | -1.2 | -17.8 | -20.0 | -22.6 | -25.4 | -28.6 |
| EBIT, % | -1939.62 | -69515.38 | -7.18 | -38.83 | -3.77 | -49.96 | -49.96 | -49.96 | -49.96 | -49.96 |
| Total Cash | 12.1 | 21.3 | 14.4 | 16.3 | 21.4 | 29.2 | 32.9 | 37.0 | 41.7 | 46.9 |
| Total Cash, percent | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .5 | .0 | 5.5 | 1.9 | 3.4 | 13.8 | 15.5 | 17.5 | 19.7 | 22.2 |
| Account Receivables, % | 49.32 | 123.08 | 25.06 | 8.71 | 10.78 | 38.78 | 38.78 | 38.78 | 38.78 | 38.78 |
| Inventories | .4 | 1.2 | .6 | .6 | .9 | 10.5 | 11.8 | 13.3 | 15.0 | 16.9 |
| Inventories, % | 39.62 | 3184.62 | 2.52 | 2.62 | 2.88 | 29.53 | 29.53 | 29.53 | 29.53 | 29.53 |
| Accounts Payable | .6 | 2.3 | 1.8 | 1.8 | 1.8 | 13.0 | 14.6 | 16.5 | 18.5 | 20.9 |
| Accounts Payable, % | 59.96 | 6010.26 | 8.13 | 8.31 | 5.84 | 36.45 | 36.45 | 36.45 | 36.45 | 36.45 |
| Capital Expenditure | -1.8 | -.1 | -3.3 | -2.8 | -.8 | -16.4 | -18.5 | -20.8 | -23.4 | -26.4 |
| Capital Expenditure, % | -192.49 | -128.21 | -14.93 | -13.12 | -2.45 | -46.1 | -46.1 | -46.1 | -46.1 | -46.1 |
| Tax Rate, % | -35.85 | -35.85 | -35.85 | -35.85 | -35.85 | -35.85 | -35.85 | -35.85 | -35.85 | -35.85 |
| EBITAT | -18.3 | -27.9 | -2.4 | -8.9 | -1.6 | -17.7 | -20.0 | -22.5 | -25.3 | -28.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -20.0 | -26.0 | -10.5 | -6.4 | -3.3 | -31.6 | -27.1 | -30.5 | -34.3 | -38.6 |
| WACC, % | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -119.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -39 | |||||||||
| Terminal Value | -459 | |||||||||
| Present Terminal Value | -278 | |||||||||
| Enterprise Value | -397 | |||||||||
| Net Debt | -16 | |||||||||
| Equity Value | -381 | |||||||||
| Diluted Shares Outstanding, MM | 26 | |||||||||
| Equity Value Per Share | -14.86 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real ETON financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the highlighted cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Eton’s valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Eton Pharmaceuticals, Inc. (ETON).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to Eton Pharmaceuticals, Inc. (ETON).
- Customizable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates relevant to Eton Pharmaceuticals, Inc. (ETON).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Eton Pharmaceuticals, Inc. (ETON).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis of Eton Pharmaceuticals, Inc. (ETON).
How It Works
- Step 1: Download the prebuilt Excel template featuring Eton Pharmaceuticals, Inc.'s (ETON) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Immediately see the recalculated results, including Eton Pharmaceuticals, Inc.'s (ETON) intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create detailed reports.
Why Choose This Calculator for Eton Pharmaceuticals, Inc. (ETON)?
- Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and industry consultants.
- Accurate Data: Eton's historical and projected financials are preloaded for precise analysis.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a smooth calculation process.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Eton Pharmaceuticals stock (ETON).
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to Eton Pharmaceuticals (ETON).
- Consultants: Deliver professional valuation insights on Eton Pharmaceuticals (ETON) to clients quickly and accurately.
- Business Owners: Understand how pharmaceutical companies like Eton Pharmaceuticals (ETON) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Eton Pharmaceuticals (ETON).
What the Template Contains
- Pre-Filled Data: Includes Eton Pharmaceuticals' historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Eton Pharmaceuticals' profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.